HC Wainwright Predicts Alpha Cognition Q1 Earnings

Alpha Cognition, Inc. (NASDAQ:ACOG) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Alpha Cognition in a report issued on Tuesday, March 18th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.72) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.02) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.67) EPS.

Alpha Cognition Price Performance

ACOG stock opened at $5.55 on Thursday. The firm has a market capitalization of $88.91 million, a P/E ratio of -2.17 and a beta of 2.50. Alpha Cognition has a twelve month low of $4.66 and a twelve month high of $7.00. The company has a 50 day moving average price of $5.92.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ACOG. Rosalind Advisors Inc. purchased a new position in Alpha Cognition in the fourth quarter worth $1,489,000. National Bank of Canada FI purchased a new position in Alpha Cognition in the fourth quarter worth $69,000. Aristides Capital LLC purchased a new position in Alpha Cognition in the fourth quarter worth $1,178,000. ADAR1 Capital Management LLC purchased a new position in Alpha Cognition in the fourth quarter worth $1,204,000. Finally, Altium Capital Management LLC purchased a new position in Alpha Cognition in the fourth quarter worth $1,620,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.